Journey Medical Corporation Q1 2026 Earnings Call Summary

Journey Medical (DERM) reported a strong performance in Q1 2026, achieving 21% year-over-year revenue growth driven by the scaling of its product Emrosi. The company secured agreements with major PBM-owned GPOs and expanded its prescriber base to over 3,700. It anticipates positive EBITDA for the remainder of 2026 due to improved revenue per prescription.

By Moby Intelligence Fri, May 15, 2026 at 3:25 AM GMT+3 3 min read · Yahoo Finance · May 15, 2026, 00:25 UTC

Tickers: $NVDA

Topics: market_expansion operating_leverage revenue_growth

Read the full article at Yahoo Finance

More World news

Global Asset Management Group Signs LOI for $100 Million Affordable Housing Portfolio in Washington, D.C. PR Newswire · November 12, 2026, 17:30 UTC
U.S. Air Conditioner and Heat Pump Shipments Increase 27.3% in September Seeking Alpha · November 12, 2026, 17:27 UTC
Nvidia CEO Jensen Huang Resigns Amid Intelligence Probe Seeking Alpha · November 12, 2026, 17:27 UTC
Oklo and Centrus Energy Sign Multi-Year HALEU Fuel Supply Agreements for Ohio Nuclear Campus Seeking Alpha · November 12, 2026, 17:28 UTC
IRS Announces Increased 401(k) Contribution Limits for 2027 CNBC · November 12, 2026, 17:23 UTC
Bit Digital Announces $865 Million Contract and Commencement of 40MW Billing Seeking Alpha · November 12, 2026, 17:20 UTC
Nvidia CEO Jensen Huang Resigns Amid Investigation and Personal Allegations Motley Fool · November 12, 2026, 17:20 UTC
Argus Research Upgrades Republic Services to Buy Seeking Alpha · November 12, 2026, 17:16 UTC
Moderna Shares Decline Following Analyst Day Projections and Future Cost Concerns Motley Fool · November 12, 2026, 17:13 UTC
United Airlines Restricts AI Agent Access to Booking Systems Due to Cybersecurity and Regulatory Concerns TechCrunch · November 12, 2026, 17:17 UTC